Combination Study for High Risk Multiple Myeloma Patients

NCT03104270 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early by Funding Sponsor due to low enrollment.

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab
DRUG: Pomalidomide
DRUG: Carfilzomib
DRUG: Dexamethasone

Sponsor

Oncotherapeutics